TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women aged 18-80 years, inclusive.~2. Drug-free outpatients or inpatients meeting DSM-IV criteria for major depression with psychotic features.~3. Inpatients who undergo a 5-7 day washout period of their medication while concurrently beginning one of the approved SSRI's and abilify.~4. HAM-D-24 score \> 16.~Exclusion Criteria:~1. Pregnant women and women of child bearing potential not using a medically accepted means of contraception (oral contraceptives are allowed).~2. Women who are breast-feeding.~3. Patients meeting DSM-IV criteria for major depression without psychotic features, or psychosis without major depression at the screen visit.~4. Patients with serious suicidal risk.~5. Patients with a history of seizure disorder; unstable physical disorders (cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic); or any physical disorder judged to significantly affect central nervous system function.~6. Patients meeting criteria for the following DSM-IV diagnoses: organic mental disorders; substance use disorders, including alcohol, active within the last 6 months; bipolar disorder; schizoaffective disorder; or antisocial personality disorder.~7. Patients who are currently taking an antidepressant, antipsychotic, or mood stabilizing drug and who are responding to one or all of these medications. If patients are not responding to these medications, they may go through a washout period of at least one week under the supervision of a study doctor before entering into this study.~8. Patients who are not able to read and understand the consent form, or who are not capable of understanding or giving informed consent to the procedures of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Major Depression with Psychotic Features (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (≥ 18 years) infected with S. stercoralis~* Absence of major systemic illnesses~* Written informed consent signed by individual~Exclusion Criteria:~* Any abnormal medical conditions or chronic disease~* Negative diagnostic result for S. stercoralis~* No written informed consent by individual.~* Pregnant and lactating women.~* Recent use of anthelmintic drug (within past 4 weeks), attending other clinical trials during the study~* Known allergy to study medications (i.e. moxidectin, ivermectin)~* Currently taking medications with known interaction (i.e. for warfarin)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Phase 2a - Arm A (Type: EXPERIMENTAL): 2 mg Moxidectin at day 0 administered orally
- Phase 2a - Arm B (Type: EXPERIMENTAL): 4 mg Moxidectin at day 0 administered orally
- Phase 2a - Arm C (Type: EXPERIMENTAL): 6 mg Moxidectin at day 0 administered orally
- Phase 2a - Arm D (Type: EXPERIMENTAL): 8 mg Moxidectin at day 0 administered orally
- Phase 2a - Arm E (Type: EXPERIMENTAL): 10 mg Moxidectin at day 0 administered orally
- Phase 2a - Arm F (Type: EXPERIMENTAL): 12 mg Moxidectin at day 0 administered orally
- Phase 2a - Arm G (Type: PLACEBO_COMPARATOR): matching Placebo tablet(s) at day 0 administered orally
- Phase 2b - Arm A (Type: EXPERIMENTAL): the recommended dose moxidectin (i.e. the most promising dosage identified in phase 2a; between 2-12 mg) at day 0 administered orally~+ Ivermectin placebo, corresponding to Phase 2b - Arm B
- Phase 2b - Arm B (Type: ACTIVE_COMPARATOR): 200 µg/kg ivermectin at day 0 administered orally~+ Moxidectin placebo, corresponding to Phase 2b - Arm A

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate Radiotherapy With or Without CBDCA in Elderly Patients With Non-Small Cell Lung Cancer (JCOG0301)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically and/or cytologically proven NSCLC~* Unresectable disease~* Stage IIIA except T3N1M0 and IIIB which does not have disease extended to any contralateral hilar nodes, atelectasis of the entire lung or malignant pleural effusions~* A required radiation field of less than one half of one lung~* Measurable disease~* No previous chemotherapy or radiotherapy~* Age \>= 71~* Unable to receive cisplatin-based combination chemotherapy~* ECOG performance status (PS) of 0-2~* Adequate bone marrow, lung, hepatic, and renal function~* Written informed consent~Exclusion Criteria:~* Active infection, diarrhea, ileus, uncontrolled diabetes, myocardial infarction within three months, or severe other comorbidity~* Synchronous cancer or metachronous (within 5 years) malignancy~* Interstitial pneumonia or active lung fibrosis on chest X-ray~* Severe chronic obstructive pulmonary disease, chronic bronchitis, or bronchial asthma~* Pleural or pericardial effusion~* A history of severe hypersensitivity~* Mental disorder~* Judging of inappropriate condition for this study by physician

- Gender: ALL
- Minimum Age: 71 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Procedure/Surgery: A: Radiotherapy alone
- 2 (Type: EXPERIMENTAL): Drug: B: CBDCA and Radiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Two Therapies for the Treatment of Osteoarticular Inflammation in Dyspeptic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults male or female aged ≥ 18 years old;~* Comply with all the purposes and procedures of the study by signing and dating the Informed Consent.~* Acute or chronic osteo-articular injury in need of of anti-inflammatory for a period of 14 days.~Exclusion Criteria:~* Pregnant women, or women in childbearing age who are not in use effective contraception or intending to become pregnant during the study period~* History of peptic ulcer or gastric surgery;~* Use of Non-steroidal anti-inflammatory (NSAIDs), aspirin, proton pump inhibitor (PPIs), H2 blocker and antacid in the past 7 days;~* Contraindication to the use of NSAIDs or PPIs;~* Renal or hepatic impairment;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Nimesulide + Pantoprazole (Type: EXPERIMENTAL): Nimesulide + Pantoprazole- 1 tablet each 12 hours for 14 days
- Naproxen + Esomeprazole (Type: ACTIVE_COMPARATOR): Naproxen + Esomeprazole - 1 tablet each 12 hours for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 2 years of age or older~* Body weight of at least 33 pounds~* Has an active head lice infestation at Day 0. An active infection is defined as at least 3 live lice for the index subject and at least 1 live louse for the other household members~* Belong to a household of no more than 6 members, except where additional household members are \< 2 years of age~* Belong to a household with an eligible index subject between 2 and 12 years of age with active lice infestation~* Female subjects must be:~  * of non-childbearing potential (no history of menstrual periods, post-hysterectomy, or, post-menopausal for at least 2 years) OR,~ * if of childbearing potential, must have a negative urine pregnancy test prior to treatment and agree to use a highly effective method of contraception from Day 0 through the Day 14 visit.~Exclusion Criteria:~* Had treatment for head lice within 14 days prior to Day 0~* Has a household member(s) who is infested with lice but is not willing or not eligible for enrollment~* Has a condition or illness that, in the opinion of the Investigator, may interfere with the study results~* Has an electrocardiographic abnormality, renal disease or impaired renal function, dermatological disease on the face, scalp, ears or neck, or active ophthalmological disease, moderate or severe scleral injection with conjunctival erythema or purulent discharge or allergic or perennial rhinitis requiring chronic treatment~* Has been using hormonal contraception for less than 3 months or is pregnant or lactating~* Has received systemic corticosteroids within 7 days prior to Day 0 or planned while on study~* Receiving systemic or topical medication, which in the opinion of the Investigator, may interfere with the study results~* Has received an investigational agent within 30 days prior to Day 0

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Group A Low-Dose Ha44 Gel 0.37% w/w topically administered to head and scalp.Single application for 10 minutes.
- Group B (Type: EXPERIMENTAL): Group B High-Dose Ha44 Gel 0.74% w/w. Topically administered to hair and scalp. Single application for 10 minutes of duration.
- Group C (Type: PLACEBO_COMPARATOR): Group C Placebo/ vehicle Ha44 Gel. Topically administered to hair and scalp.Single application for 10 minutes of duration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Median Nerve Stimulation Pilot

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 15-64 inclusive at initial screening visit~* Informed consent by adult subject; assent by child and informed consent by guardian~* Current Tourette's Disorder or Persistent (Chronic) Tic Disorder according to the criteria in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5~* At least 1 tic per minute (average) during the first 5-min. baseline video session on the first visit (as scored during the session by the investigator)~Exclusion Criteria:~* Unable to complete study procedures for any reason~* Has an implanted device that could be affected by electrical current~* Pregnancy known to participant or (for children) to the parent~* Known or suspected primary genetic syndrome (e.g. Down syndrome, Fragile X)~* Intellectual disability (known, or likely from history and examination)~* Head trauma with loss of consciousness for more than 5 minutes~* Significant neurologic disease, not counting TS (exceptions include febrile seizures or uncomplicated migraine)~* Severe or unstable systemic illness~* Factors (such as exaggerated signs) that in the judgment of the principal investigator make the video recording or YGTSS an inaccurate assessment of tic severity~* Judged by investigator to be unlikely to complete study procedures or to return for later visits~* Change in somatic or psychotherapeutic treatment in the 2 weeks preceding the first stimulation visit~* Planned change in somatic or psychotherapeutic treatment between the 2 stimulation visits

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Experimental: rhythmic MNS, then arrhythmic MNS (Type: OTHER): Participants will complete two stimulation sessions, at least a week apart. The first session involves rhythmic MNS and the second uses arrhythmic MNS.
- Experimental: arrhythmic MNS, then rhythmic MNS (Type: OTHER): Participants will complete two stimulation sessions, at least a week apart. The first session involves arrhythmic MNS and the second uses rhythmic MNS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Intravenous Erythromycin on Gastric Emptying in Non-fasted Patients Before Emergency Total Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults, age ≥18 years, male or female.~* American Society of Anaesthesiology \[ASA\] status I, II or III.~* Non-starving patients presenting for surgery.~* Patients able to read and understand the information sheet and to sign the consent form.~* If the patient is female and of childbearing potential, she must have a negative pregnancy test~Exclusion Criteria:~* A history of allergy or hypersensitivity to erythromycin or other macrolides.~* Concomitant use of terfenadine, astemizole, cisapride, pimozid, cyclosporine, clarithromycine.~* Patient with acute intermittent porphyria.~* Acute or subacute necrosis of the liver, acute or subacute hepatitis, acute liver trauma~* Acute renal failure, acute glomerulonephritis, nephritic syndrome, chronic renal failure with electrolyte disorders, uremia~* Exacerbated asthma, exacerbated chronic obstructive lung disease, acute pulmonary infection~* Coronary heart disease (unstable angina, MI within the last 6 months), decompensated cardiac insufficiency, aortic aneurysm~* Polyneuropathy (for instance, due to diabetes mellitus)~* Patients with oesophageal and pharyngeal disease (i.e. oesophageal varices, oesophageal and pharyngeal cancer, Zenker's diverticulum).~* Status after gastric surgery, gastric bypass surgery, Nissen operation~* Patients with life threatening illness or injury needing immediate surgery~* Patients with moderate to severe head trauma (GCS on admission \<13)~* Psychological or psychiatric disorders.~* Dementia or inability to understand the study protocol.~* Women who are pregnant or are breast feeding.~* Patient scheduled for ileus surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Physiologic saline (Type: PLACEBO_COMPARATOR): None
- Erythromycine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Renal transplant CMV-Seropositive~* CD8+ Tcell CMV especific pretransplant (CMV-reactive quantiferon pretrasplant)~* \> 18 years (adult)~* Receiving Thymoglobulin induction therapy~* Receiving Valganciclovir prophylaxis~* Written informed consent for trial entry~Exclusion Criteria:~* Multivisceral transplants including kidney-pancreas.~* HIV-infected Patients~* Patients who can not comply with the monitoring protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- New profilaxis (Type: EXPERIMENTAL): Prophylaxis is discontinued when the patient developed CMV-specific cellular immunity.
- Profilaxis recommended by TTS (Type: ACTIVE_COMPARATOR): Valganciclovir prophylaxis until day +90 as recommended by the International Consensus document of the TTS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Amlodipine Versus Bisoprolol on Hypertensive Patients With End-stage Renal Disease on Maintenance Hemodialysis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* On maintenance hemodialysis 3 times weekly for at least 3 months.~* Hypertensive as determined by predialytic BP \> 140/ 90, post-dialytic \> 130/80, home-measured BP \>140/90, Office based BP \>140/90 and/or on antihypertensive medication.~Exclusion Criteria:~* History of malignancy.~* History of significant valvular heart disease.~* Chronic congestive heart failure.~* History of coronary artery disease.~* Ongoing atrial fibrillation.~* Known drug abuse.~* Known contraindication to Bisoprolol or Amlodipine.~* History of MI~* History of Stroke

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Amlodipine (Type: EXPERIMENTAL): Hypertensive patients on dialysis receiving Amlodipine 5-10 mg tablet daily alone or as part of antihypertensive regimen.
- Bisoprolol (Type: EXPERIMENTAL): Hypertensive patients on dialysis receiving Bisoprolol 5-10 mg tablet daily alone or as part of antihypertensive regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with open angle glaucoma or ocular hypertension~Exclusion Criteria:~* Patients at risk of progression of visual field loss~* Patients with severe visual field defect~* Patients with any diseases that preclude participation in this study for safety reasons

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DE-117 ophthalmic solution (Group1) (Type: EXPERIMENTAL): Monotherapy
- DE-117 ophthalmic solution (Group2) (Type: EXPERIMENTAL): Monotherapy
- DE-117 ophthalmic solution + Timolol (Group3) (Type: OTHER): Concomitant Use

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Autologous Hematopoietic Stem Cell Transplantation for Early Onset Type 1 Diabetes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes mellitus diagnosed by clinical/metabolic parameters and positive anti-GAD antibody~* Less than 6 months from diagnosis~Exclusion Criteria:~* Previous diabetic ketoacidosis~* Pregnancy~* Severe psychiatric disorder~* Severe organic impairment (renal, hepatic, cardiac, pulmonary)~* Active infectious disease~* Previous or present neoplastic disease

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- insulin therapy (Type: ACTIVE_COMPARATOR): The participants not accepted written informed consent will receive insulin therapy
- AHSCT (Type: EXPERIMENTAL): The participants accepted written informed consent will receive the therapy of autologous hematopoietic stem cell transplantation(AHSCT)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:- Must have evidence of ovarian cancer measurable by computed tomography (CT) scan or by CA125 blood levels- No radiation therapy in last 4 weeks- No chemotherapy in last 24 weeks - No immunotherapy in last 4 weeks- Good response after previous treatment with carboplatin or cisplatin and then the ovarian cancer got worse again after at least 6 months- Additional criteria determined at screening visit Exclusion Criteria:- Having had more than one treatment regimen with carboplatin or cisplatin- Prior treatment with other epothilones (e.g. ixabepilone)- Use of any investigational drug in the last 4 weeks- Previous radiation to the whole pelvis- Symptomatic brain tumors requiring radiation to the brain - Active infection- Pregnant or breast feeding- Additional criteria determined at screening visit

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete